Page 41 - TD-2-2

Tumor Discovery A comprehensive review of bexarotene

46. Tu L, Yang XL, Zhang Q, et al., 2018, Bexarotene attenuates Transl Res, 10(6): 1688–1699.
early brain injury via inhibiting micoglia activation through https://doi.org/10.1007/s13346-020-00816-2
PPARγ after experimental subarachnoid hemorrhage.
Neurol Res, 40(8): 702–708. 57. Zhang Q, Lee SB, Chen X, et al., 2019, Optimized Bexarotene
aerosol formulation inhibits major subtypes of lung cancer
https://doi.org/10.1080/01616412.2018.1463900
in mice. Nano Lett, 19: 2231−2242.
47. Yuan C, Dai C, Li Z, et al., 2020, Bexarotene improve https://doi.org/10.1021/acs.nanolett.8b04309
depression-like behaviour in mice by protecting against
neuro-inflammation and synaptic damage. Neurochem Res, 58. Vasile A, Ignat M, Zaltariov MF, et al., 2018, Development of
45(7): 1500–1509. new Bexarotene-loaded mesoporous silica systems for topical
pharmaceutical formulations. Acta Chim Slov, 65(1): 97–107.
https://doi.org/10.1007/s11064-020-03012-3
59. Lee JB, Kim TH, Feng W, et al., 2019, Quantitative prediction
48. Mahajan A, Kaur L, Singh G, et al., 2022, COVID19 vaccines: of oral bioavailability of a lipophilic antineoplastic drug
Fabrication techniques and current status. Coronaviruses, bexarotene administered in lipidic formulation using
3(1): 42–48.
a combined in vitro lipolysis/microsomal metabolism
49. Yuan S, Chan JFW, Chik KKH, et al., 2020, Discovery approach. J Pharm Sci, 108(2): 1047–1052.
of the FDA-approved drugs bexarotene, cetilistat, https://doi.org/10.1016/j.xphs.2018.09.025
diiodohydroxyquinoline, and abiraterone as potential
COVID-19 treatments with a robust two-tier screening 60. Singh L, Kaur L, Singh G, et al., 2022, Determination of
system. Pharmacol Res, 159: 104960. alteration in micromeritic properties of a solid dispersion:
Brunauer-Emmett-Teller based adsorption and other
https://doi.org/10.1016/j.phrs.2020.104960 structured approaches. AAPS PharmSciTech, 23(6): 209.
50. Shahabadi N, Zendehcheshm S, Mahdavi M, et al., 2021, 61. Xiao F, Cheng Y, Wang JR, et al., 2022, Cocrystal prediction
Inhibitory activity of FDA-approved drugs cetilistat, of bexarotene by graph convolution network and
abiraterone, diiodohydroxyquinoline, bexarotene, bioavailability improvement. Pharmaceutics, 14(10): 2198.
remdesivir, and hydroxychloroquine on COVID-19 main
protease and human ACE2 receptor: A comparative in silico https://doi.org/10.3390/pharmaceutics14102198
approach. Inform Med Unlocked, 26: 100745. 62. Kryczyk-Poprawa A, Zupkó I, Bérdi P, et al., 2021,
https://doi.org/10.1016/j.imu.2021.100745 Photodegradation of Bexarotene and its implication for
cytotoxicity. Pharmaceutics, 13(8): 1220.
51. Kobayashi T, Mitsuhashi A, Hongying P, et al., 2022,
Bexaroteneinduced cell death in ovarian cancer cells https://doi.org/10.3390/pharmaceutics13081220
through Caspase4gasdermin E mediated pyroptosis. Sci Rep, 63. Toi N, Kurajoh M, Miyaoka D, et al., 2022, Bexarotene-
12: 11123. induced central hypothyroidism assessed by TRH
https://doi.org/10.1038/s41598-022-15348-7 stimulation test in cutaneous T-cell lymphoma patients.
Endocr J, 69(1): 101–105.
52. Hurst RE, 2000, Bexarotene ligand pharmaceuticals. Curr
Opin Investig Drugs, 1(4): 514–523. https://doi.org/10.1507/endocrj.EJ21-0313
53. FDA Approves Ligand’s Targretin Gel, 2023. Available from: 64. Makita N, Manaka K, Sato J, et al., 2019, Bexarotene-induced
https://www.thepharmaletter.com/article/fda-approves- hypothyroidism: Characteristics and therapeutic strategies.
ligand-s-targretin-gel [Last accessed on 2023 Aug 01]. Clin Endocrinol (Oxf), 91(1): 195–200.
54. Eisai and Minophagen Pharmaceutical Conclude https://doi.org/10.1111/cen.13975
License Agreement Concerning the Development and 65. Chiang ACA, Seua AV, Singhmar P, et al., 2020, Bexarotene
Commercialization of Cutaneous T-Cell Lymphoma normalizes chemotherapy-induced myelin decompaction
Treatment Bexarotene in Asia, Oceania, the Middle East and and reverses cognitive and sensorimotor deficits in mice.
Eastern Europe, 2023. Available from: https://www.eisai.com/ Acta Neuropathol Commun, 8: 193.
news/news201212.html [Last accessed on 2023 Aug 01].
https://doi.org/10.1186/s40478-020-01061-x
55. Saka R, Jain H, Kommineni N, et al., 2020, Enhanced
penetration and improved therapeutic efficacy of Bexarotene 66. Hacioglu C, Kar F, Kacar S, et al., 2021, Bexarotene inhibits
via topical liposomal gel in imiquimod induced 16 psoriatic cell proliferation by inducing oxidative stress, DNA damage
plaque model in BALB/c mice. J Drug Deliv Sci Technol, and apoptosis via PPARγ/NF-κB signaling pathway in C6
58: 101691. glioma cells. Med Oncol, 38(3): 31.
https://doi.org/10.1007/s12032-021-01476-z
56. de Oliveira ER Jr., Santos LCR, Salomão MA, et al., 2020,
Nose-to-brain drug delivery mediated by polymeric 67. Ning Z, 2008, CN100434068C, Bexarotene Gel and its
nanoparticles: Influence of PEG surface coating. Drug Deliv Preparation Method.

Volume 2 Issue 2 (2023) 15 https://doi.org/10.36922/td.0436